Company intelligence / Profile preview

Lexent Bio

San Francisco, California, United Statesfoundationmedicine.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Lexent Bio was developing liquid biopsy technology for monitoring minimal residual disease in solid tumors and measuring patient response to therapy. The company was working on an in vitro diagnostic based on whole-genome sequencing and DNA methylation analysis.

Therapeutic areas: Oncology
Modalities: Liquid biopsy technology
Industry: Molecular Diagnostics

Partnerships

Illumina (development deal in November 2019)

Beyond the preview

Go deeper on Lexent Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lexent Bio.

Explore the full profile